Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Mauro Ferrari Sells 8,750 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Mauro Ferrari sold 8,750 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $56.39, for a total value of $493,412.50. Following the completion of the transaction, the director owned 68,764 shares of the company’s stock, valued at approximately $3,877,601.96. This represents a 11.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Arrowhead Pharmaceuticals Stock Up 6.7%

Shares of NASDAQ ARWR traded up $3.55 during trading on Monday, reaching $56.25. 3,323,871 shares of the stock were exchanged, compared to its average volume of 2,088,561. The company has a market capitalization of $7.64 billion, a price-to-earnings ratio of -43.95 and a beta of 1.27. The business’s 50-day moving average price is $39.14 and its 200 day moving average price is $26.05. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $59.15.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Moody Lynn & Lieberson LLC bought a new position in Arrowhead Pharmaceuticals during the second quarter valued at about $213,000. CWM LLC grew its position in Arrowhead Pharmaceuticals by 159.4% in the second quarter. CWM LLC now owns 11,415 shares of the biotechnology company’s stock worth $180,000 after buying an additional 7,014 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 1st quarter worth $173,000. Pinnacle Associates Ltd. raised its position in shares of Arrowhead Pharmaceuticals by 49.9% during the second quarter. Pinnacle Associates Ltd. now owns 211,561 shares of the biotechnology company’s stock worth $3,343,000 after purchasing an additional 70,399 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 75.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,308 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ARWR shares. Morgan Stanley boosted their price target on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 26th. Royal Bank Of Canada raised their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday. The Goldman Sachs Group increased their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a research note on Thursday, November 20th. Finally, Bank of America boosted their target price on shares of Arrowhead Pharmaceuticals from $42.00 to $62.00 and gave the stock a “buy” rating in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $52.78.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.